LexDanaLexDanabeta
Inventor

Liansheng Li

Inventor
San Diego, CA, US

Overview

91→
Patents
2008–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 91 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
A61KPreparations for medical, dental or toiletry purposes20%
Y02ATechnologies for adaptation to climate change7%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A61NElectrotherapy2%
Y02PClimate change mitigation technologies in the production or processing of goods2%
C07BGeneral methods of organic chemistry2%
C12NMicroorganisms or enzymes2%
PatentTitleYear
11,128,857Intra prediction-based image coding method using MPM list and apparatus therefor202111,099,313Customized polymer/glass diffractive waveguide stacks for augmented reality/mixed reality applications202111,061,974Facilitating discovery of information items using dynamic knowledge graph202111,057,619Image coding method and apparatus based on intra prediction using MPM list202110,875,842Inhibitors of KRAS G12C mutant proteins202010,858,343Inhibitors of KRAS G12C mutant proteins202010,829,458Substituted quinazoline compounds and methods of use thereof202010,822,312Substituted quinazoline compounds and methods of use202010,781,218Substituted inhibitors of menin-MLL and methods of use202010,752,639Bridged bicyclic inhibitors of menin-MLL and methods of use202010,745,385Covalent inhibitors of KRAS202010,736,897Compounds and methods of use thereof for treatment of cancer202010,730,867Inhibitors of KRAS G12C mutant proteins202010,723,738Inhibitors of KRAS G12C mutant proteins202010,689,356Inhibitors of KRAS G12C mutant proteins202010,646,488Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof202010,647,703Inhibitors of KRAS G12C mutant proteins202010,588,907Methods and compositions for inhibiting the interaction of menin with MLL proteins202010,428,064Fused-tricyclic inhibitors of KRAS and methods of use thereof201910,414,7572-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof201910,377,743Inhibitors of RAS and methods of use thereof201910,370,386Substituted quinolines as inhibitors of KRAS G12C201910,351,550Substituted quinazoline compounds and methods of use thereof201910,301,317Inhibitors of ERK and methods of use201910,280,172Inhibitors of KRAS G12C mutant proteins201910,273,207Covalent inhibitors of kras G12C201910,246,424Substituted quinazoline compounds and methods of use thereof201910,246,464Thienopyrimidine and thienopyridine compounds and methods of use thereof201910,174,041Methods and compositions for inhibiting the interaction of menin with MLL proteins201910,144,724Substituted quinazoline compounds and methods of use thereof201810,111,874Combination therapies for treatment of cancer201810,077,271Methods and compositions for inhibiting the interaction of menin with MLL proteins201810,011,600Methods and compositions for inhibition of Ras20189,988,357Methods for preparation of quinazoline derivatives20189,951,078Inhibitors of ERK and methods of use20189,926,267'Covalent inhibitors of K-Ras G12C'20189,862,701'Inhibitors of KRAS G12C mutant proteins'20189,840,516'Substituted quinazolines as inhibitors of KRAS G12C'20179,828,378Kinase inhibitors and methods of use20179,822,131'Certain chemical entities, compositions and methods'20179,810,690'Method for screening inhibitors of Ras'20179,790,228'Heterocyclic kinase inhibitors'20179,745,319'Irreversible covalent inhibitors of the GTPase K-Ras G12C'20179,738,644'Chemical compounds, compositions and methods for kinase modulation'20179,718,815'Heterocyclic compounds and uses thereof'20179,655,892'Certain chemical entities, compositions and methods'20179,637,492'Benzothiazole kinase inhibitors and methods of use'20179,629,843'MTOR modulators and uses thereof'20179,624,228'Inhibitors of ERK and methods of use'20179,605,003'Heterocyclic compounds and uses thereof'20179,546,180'Heterocyclic compounds and uses thereof'20179,522,146'Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20169,388,183'Heterocyclic compounds and uses thereof'20169,359,352'Substituted benzimidazoles as PI3 kinase inhibitors'20169,345,706'Benzoxazole kinase inhibitors and methods of use'20169,315,505'Heterocyclic compounds and uses thereof'20169,296,742'Heterocyclic kinase inhibitors'20169,255,108'Heterocyclic compounds and uses thereof'20169,227,978'Covalent inhibitors of Kras G12C'20169,216,982'Certain chemical entities, compositions and methods'20159,206,182'Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20159,181,221'Chemical compounds, compositions and methods for kinase modulation'20159,127,000'Heterocyclic compounds and uses thereof'20159,115,141'Substituted isoquinolinones and methods of treatment thereof'20159,096,611'Kinase inhibitors and methods of use'20159,096,590'Substituted benzoxazoles as PI3 kinase inhibitors'20159,085,560'Heterocyclic compounds and uses thereof'20159,056,877'Heterocyclic compounds and uses thereof'20158,993,580'Benzothiazole kinase inhibitors and methods of use'20158,969,363'Heterocyclic compounds and uses thereof'20158,940,742'Heterocyclic compounds and uses thereof'20158,901,133'Heterocyclic compounds and uses thereof'20148,785,454'Heterocyclic compounds and uses thereof'20148,785,470'Heterocyclic compounds and uses thereof'20148,785,456'Substituted isoquinolin-1(2H)-ones, and methods of use thereof'20148,703,778'Heterocyclic kinase inhibitors'20148,703,777'Certain chemical entities, compositions and methods'20148,637,542'Kinase inhibitors and methods of use'20148,604,032'Chemical compounds, compositions and methods for kinase modulation'20138,569,323'Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20138,476,282'Benzoxazole kinase inhibitors and methods of use'20138,476,431'Benzoxazole kinase inhibitors and methods of use'20138,450,329'Benzoxazole kinase inhibitors and methods of use'20138,450,480'Benzoxazole kinase inhibitors and methods of use'20138,193,182'Substituted isoquinolin-1(2H)-ones, and methods of use thereof'20127,842,838'Pyrro[1,2-b]pyridazinone intermediates'20107,834,009'4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds'20107,582,754'Pyrro[1,2-b]pyridazinone compounds'20097,462,611'Pyrro[1,2-b]pyridazinone compounds'20087,425,552'Pyridazinone compounds'20087,361,743'Lincomycin derivatives possessing antibacterial activity'2008

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2008–2020Based in San Diego, CA, US· patent location history
2012–2015Patents assigned to LI LIANSHENG (19)· patent assignee history
2012–2015Patents assigned to LIU YI (19)· patent assignee history
2012–2015Patents assigned to REN PINGDA (19)· patent assignee history
2013–2017Patents assigned to INTELLIKINE LLC (23)· patent assignee history
2016–2020Patents assigned to ARAXES PHARMA LLC (29)· patent assignee history
2019Based in La Jolla, CA, US· patent location history
2021Based in Seoul, KR· patent location history
2021Based in Cedar Park, TX, US· patent location history
2021Based in Beijing, CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ARAXES PHARMA LLC292016–2020
INTELLIKINE LLC232013–2017
LI LIANSHENGself192012–2015
LIU YI192012–2015
REN PINGDA192012–2015
Locations
LocationPatentsSpan
San Diego, California, US862008–2020
Seoul, KR22021
Cedar Park, Texas, US12021
Beijing, CN12021
La Jolla, California, US12019